FIC 2026 Interview | Bioyitech: Building Full-Chain Microecological Solutions Centered on Metabolic Health
Food Ingredients China is the world’s largest and most international professional exhibition for the food additives and ingredients industry.It brings together all top international giants such as Cargill, IFF, and DSM-Firmenich, making it the preferred platform for companies to launch new products.Through the Food Industry Academician Forum and the China-International Regulations and Standards Forum,” it establishes a high-end and professional exchange system.
With an exhibition area of nearly 170,000 square meters, approximately 1,672 exhibitors, and close to 150,000 professional visitors, it firmly holds a dominant position in the industry.As a key hub connecting China and the global food industry, it serves not only as a core venue for global supply chain business matching but also as a bellwether for industry innovation.Closely following cutting-edge trends such as synthetic biology and green manufacturing, it continues to lead the industry’s technological transformation and high-quality development.
At the recently concluded FIC 2026 exhibition held from March 17 to 19, Bioyitech made its presence felt with a clear positioning as the “Metabolic Health Microecological Solution Expert,” showcasing its systematic capabilities spanning from strain resources to end-user applications. Xia Ruifeng, the company’s Marketing Director, shared in an interview: “As brand customers continue to raise their requirements for functional validation, application implementation, and supply chain stability, single ingredients are no longer sufficient to support product competitiveness. Relying on its strain library of over 6,000 strains, a matrix of more than 100 functional strains, and an ‘industry-academia-research-medicine’ closed-loop system, Bioyitech is providing comprehensive end-to-end solution support—from source strains to final products.”
At the FIC exhibition, Bioyitech focused on its core strategy of Metabolic Health, showcasing a diverse portfolio covering probiotic raw materials, Postbiotics, starter cultures, and end-user products. Its flagship strain, Bifidobacterium animalis subsp. lactis F1-7, backed by two invention patents and ten academic papers, demonstrates outstanding efficacy in gut health, weight management, and blood glucose management. The “Jiang Xiaoyi” series of compound proBiotic Powders addresses key concerns related to metabolic syndrome with clinically validated formulas, solving the industry-wide challenge of lacking clinical evidence for strain functionality claims. The Vegafit Postbiotic series, developed using plant-based fermentation technology, offers high stability and broad applicability, overcoming the challenge of low probiotic survival rates in high-temperature processing scenarios such as baking. The plant-based and dairy starter cultures help customers achieve domestic substitution of industrial strains, broaden flavor profiles, and enhance supply chain security. End-user products such as the “Xiaoyi Series” ready-to-eat lactic acid bacteria powder and probiotic fermented carrot drink intuitively demonstrate the company’s ability to deliver solutions from raw materials to finished applications.
Positioning itself as a solution provider, Bioyitech relies on an integrated capability system of “in-depth R&D, agile manufacturing, and solution-oriented services.” The “industry-academia-research-medicine” closed-loop system, led by Chief Scientist Professor Zhang Lanwei, ensures source innovation and clinical validation. A Class 100 cleanroom and international certifications guarantee quality, while on-site engineering support services provide end-to-end assistance “from the conference room to the production line.” In terms of collaborative innovation, the company is exploring the combination of plant extracts with microecologics, a “co-opetition” model for joint development with international brands, and process optimization services that go deep into production, continuously redefining the boundaries of microecological innovation.
In the international market, Bioyitech is using Southeast Asia as a strategic pivot, leveraging HALAL certification and a 30%–50% cost advantage for rapid market entry, while simultaneously pursuing authoritative certifications such as EFSA and FDA GRAS in Europe and the United States to establish itself as a technology benchmark. The company also plans to extend its human probiotic technologies into the animal nutrition sector in South America, creating cross-sector synergies. On the technology front, AI is driving a shift from experience-driven to data-driven approaches in strain screening and fermentation processes, and its future integration with synthetic biology is expected to enable the targeted development of strains.
Looking ahead, Bioyitech will continue to deepen its focus on metabolic health while expanding into emerging areas such as sports health, women’s health, children’s growth, elderly musculoskeletal health, and pet health. By strengthening its B-end demonstration value through fermented fruit and vegetable beverages, the company is committed to becoming a global platform enterprise providing microecological health solutions.